<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788071</url>
  </required_header>
  <id_info>
    <org_study_id>H-15016343</org_study_id>
    <nct_id>NCT02788071</nct_id>
  </id_info>
  <brief_title>Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome</brief_title>
  <official_title>Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome (IBS) - a Randomized, Double-blind Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aleris-Hamlet Hospitaler København</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aleris-Hamlet Hospitaler København</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if fecal microbiota transplantation (FMT) will
      result in improvement in clinical outcome in patients with irritable bowel syndrome (IBS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable bowel syndrome (IBS) is the most commonly diagnosed gastrointestinal condition. IBS
      is associated with a high use of health-care costs and can substantially reduce quality of
      life and work productivity.

      Several studies have demonstrated that the composition of the gut microbiota in IBS patients
      is different from healthy controls.

      Fecal microbiota transplantation (FMT) could therefore be a treatment option for IBS patients
      by exchanging the microbiota of an IBS patient with the microbiota of a healthy donor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptoms score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by the Irritable bowel syndrome - severity symptom score (IBS-SSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota diversity</measure>
    <time_frame>Day 4, 4 weeks, 12 weeks and 24 weeks</time_frame>
    <description>Measured by DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity IBS patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota diversity in healthy donors</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by DNA sequencing. To compare with the recipients (IBS patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Irritable Bowel Syndrome-Quality of Life (IBS-QOL) Questionnaire Scores</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>FMT capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FMT capsules</intervention_name>
    <description>25 capsules per day for 12 days</description>
    <arm_group_label>FMT capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FMT placebo</intervention_name>
    <description>25 capsules per day for 12 days</description>
    <arm_group_label>FMT placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilled Rome III diagnostic criteria for IBS

          -  Moderate-severe disease activity (IBS-Symptom Severity Score ≥175)

          -  Able to read and speak Danish

          -  Normal colonoscopy at age ≥ 40 years (performed within 1 year) or blood in stool

        Exclusion Criteria:

          -  Other chronic gastrointestinal disease

          -  Positive fecal sample with enteropathogenic microorganisms or Clostridium difficile

          -  Positive screening for HIV, Hepatitis B or HCV antibody

          -  Surgical interventions in the gastrointestinal region (except for appendectomy, hernia
             repair, cholecystectomy, and gynecological and urological procedures)

          -  Psychiatric disorder

          -  Fecal calprotectin ≥ 50 mg/kg

          -  Abuse of alcohol or drugs

          -  Medications other than birth control pills, hormone supplements, allergies and asthma
             agents, blood pressure and cholesterol lowering agents, proton pump inhibitors and
             non-prescription medicines

          -  Abnormal screening biochemistry

          -  Abnormal colonoscopy findings

          -  Pregnant, planned pregnancy or breastfeeding females

          -  Ingestion of probiotics or antibiotics &lt; 8 weeks before the inclusion

        Inclusion criteria for donors

          -  Age between 18-45 years

          -  Past and current healthy

          -  Normal weight (BMI between 18,5-24,9 kg/m2)

          -  Normal bowel movements (defined as 1-2 per day and type 3-4 at Bristol Stool Form
             Scale)

          -  No medication consumption

        Exclusion criteria for donors

          -  Known or high risk of infectious diseases such as HIV, hepatitis A, B or C

          -  Positive stool sample for C. difficile toxin, parasites or other pathogens

          -  Antibiotic treatment in the past 6 months

          -  Abuse of alcohol or drugs

          -  Smoking

          -  Tattoo or body piercing within the last 6 months

          -  Allergy, asthma or eczema

          -  Family history of gastrointestinal diseases

          -  Participation in high-risk sexual behaviors

          -  Born by Caesarean section
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Højer Christensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aleris-Hamlet Hospitaler København</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aleris Hamlet Hospitaler, København</name>
      <address>
        <city>Copenhagen</city>
        <state>Søborg</state>
        <zip>2760</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>May 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aleris-Hamlet Hospitaler København</investigator_affiliation>
    <investigator_full_name>Alice Højer Christensen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

